Mackenzie Financial Corp Lowers Stock Holdings in ADMA Biologics Inc (NASDAQ:ADMA)

Mackenzie Financial Corp lowered its stake in ADMA Biologics Inc (NASDAQ:ADMAFree Report) by 7.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,673 shares of the biotechnology company’s stock after selling 5,866 shares during the period. Mackenzie Financial Corp’s holdings in ADMA Biologics were worth $1,362,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Skandinaviska Enskilda Banken AB publ acquired a new stake in ADMA Biologics in the 1st quarter valued at about $35,000. Tsfg LLC acquired a new stake in ADMA Biologics in the 1st quarter valued at about $51,000. Farther Finance Advisors LLC raised its position in ADMA Biologics by 1,149.1% in the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 2,505 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in ADMA Biologics in the 4th quarter valued at about $85,000. Finally, CIBC Private Wealth Group LLC raised its position in ADMA Biologics by 137.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 2,954 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

ADMA has been the topic of a number of analyst reports. Wall Street Zen lowered ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. Raymond James Financial increased their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research report on Thursday, May 8th.

View Our Latest Research Report on ADMA

Insider Transactions at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the sale, the director owned 94,830 shares of the company’s stock, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the transaction, the director directly owned 87,330 shares in the company, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 464,621 shares of company stock valued at $9,644,269. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $19.91 on Tuesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. ADMA Biologics Inc has a fifty-two week low of $10.21 and a fifty-two week high of $25.67. The firm has a market capitalization of $4.75 billion, a PE ratio of 23.42 and a beta of 0.38. The stock’s 50-day simple moving average is $18.81 and its 200-day simple moving average is $18.78.

ADMA Biologics (NASDAQ:ADMAGet Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. During the same period last year, the business posted $0.08 EPS. ADMA Biologics’s revenue was up 40.2% on a year-over-year basis. As a group, equities research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

About ADMA Biologics

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Recommended Stories

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMAFree Report).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.